美国监狱丙肝检测、治疗及出狱衔接的成本效果与预算影响
研究采用个体模拟模型,从医疗与惩教部门视角评估美国监狱丙肝检测、治疗及出狱衔接策略。与不检测不治疗不衔接相比,全员检测全员治疗并出狱衔接可使终身持续病毒学应答提高23%、肝硬化减少54%,每名入狱者每年额外花费1440美元且具成本效果。当前药价下靶向检测与基于纤维化治疗成本更高或效果更差。
要点
- 全员检测全员治疗并出狱衔接可提高终身SVR 23%、减少肝硬化54%。
- 该策略每名入狱者每年额外花费1440美元,具成本效果。
- 当前药价下靶向检测与基于纤维化治疗成本更高或效果更差。
核心结论
- 尽管费用高昂,当前药价下监狱内广泛检测与治疗被认为具有良好价值。
研究设计与样本
- 采用个体模拟模型,从医疗与惩教部门视角分别进行成本效果与预算影响分析。
- 模拟美国监狱入狱队列,使用已发表数据与华盛顿州惩教部门个体水平数据。
- 考虑检测、治疗与出狱衔接策略的不同组合。
主要发现
- 与不检测不治疗不衔接相比,全员检测全员治疗并出狱衔接使终身持续病毒学应答提高23%。
- 该策略使肝硬化病例减少54%,每名入狱者每年额外花费1440美元(2016年美元)。
- 当前药价下,靶向检测与基于肝纤维化治疗成本更高或每获得QALY成本更高。
- 敏感性分析中,基于纤维化治疗限制在既往较高药价下具成本效果。
关键数值与推荐
- 全员检测全员治疗并出狱衔接:终身SVR提高23%,肝硬化减少54%,每名入狱者每年额外花费1440美元,具成本效果。
- 当前药价下靶向检测与基于纤维化治疗:成本更高或效果更差。
临床怎么用
- 当前药价下可考虑在监狱实施广泛HCV检测与治疗并衔接出狱后照护。
- 基于纤维化限制治疗在当前药价下可能不是优选策略。
局限性
- 模型基于已发表数据与华盛顿州惩教部门个体数据,外推至其他州需谨慎。
- 成本以2016年美元计,药物价格变化可能影响结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus (HCV) testing and treatment uptake in prisons remains low. We aimed to estimate clinical outcomes, cost-effectiveness (CE), and budgetary impact (BI) of HCV testing and treatment in United States (US) prisons or linkage to care at release. METHODS: We used individual-based simulation modeling with healthcare and Department of Corrections (DOC) perspectives for CE and BI analyses, respectively. We simulated a US prison cohort at entry using published data and Washington State DOC individual-level data. We considered permutations of testing (risk factor based, routine at entry or at release, no testing), treatment (if liver fibrosis stage ≥F3, for all HCV infected or no treatment), and linkage to care (at release or no linkage). Outcomes included quality-adjusted life-years (QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effectiveness ratios; DOC costs (2016 US dollars); and BI (healthcare cost/prison entrant) to generalize to other states. RESULTS: Compared to "no testing, no treatment, and no linkage to care," the "test all, treat all, and linkage to care at release" model increased the lifetime sustained virologic response by 23%, reduced cirrhosis cases by 54% at a DOC annual additional cost of $1440 per prison entrant, and would be cost-effective. At current drug prices, targeted testing and liver fibrosis-based treatment provided worse outcomes at higher cost or worse outcomes at higher cost per QALY gained. In sensitivity analysis, fibrosis-based treatment restrictions were cost-effective at previous higher drug costs. CONCLUSIONS: Although costly, widespread testing and treatment in prisons is considered to be of good value at current drug prices.
引用
- Assoumou SA, Tasillo A, Vellozzi C, et al. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons. Clin Infect Dis. 2020. PMID: 31095676. doi:10.1093/cid/ciz383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。